ライフサイエンスコーパス: antibacterial drug

1 ure-based design of a potent, broad-spectrum antibacterial drug.

2 sents a highly attractive target for a novel antibacterial drug.

3 c fosfomycin, rendering it ineffective as an antibacterial drug.

4 substantially reward the development of new antibacterial drugs.

5 and examining this step as a target for new antibacterial drugs.

6 ify essential genes encoding new targets for antibacterial drugs.

7 (Topo IV) are cellular targets of quinolone antibacterial drugs.

8 tentially be used for the development of new antibacterial drugs.

9 ction and its interaction with the quinolone antibacterial drugs.

10 thase systems and is an important target for antibacterial drugs.

11 in the absence or presence of anticancer or antibacterial drugs.

12 promising targets for the development of new antibacterial drugs.

13 to be a promising target for broad-spectrum antibacterial drugs.

14 ure and evaluating the impact of concomitant antibacterial drugs.

15 ents to guide and perform quality studies of antibacterial drugs.

16 CV) on the pathways to a number of important antibacterial drugs.

17 tivize companies to invest in developing new antibacterial drugs.

18 -known and validated target in the design of antibacterial drugs.

19 stal binding pocket altering specificity for antibacterial drugs.

20 attractive, important targets for developing antibacterial drugs.

21 polymerase (RNAP) is a validated target for antibacterial drugs.

22 ported DNA segments and cleavage-stabilizing antibacterial drugs.

23 gest that it could be a potential target for antibacterial drugs.

24 topoisomerases could be developed into novel antibacterial drugs.

25 host cells and an attractive target for new antibacterial drugs.

26 ppealing target for the development of novel antibacterial drugs.

27 hyX is a potential target for development of antibacterial drugs.

28 f antitumor, antiviral, antitrypanosomal and antibacterial drugs.

29 in humans, gyrase is a successful target for antibacterial drugs.

30 sign for novel, selective YopH inhibitors as antibacterial drugs.

31 flux pump, which is able to extrude selected antibacterial drugs and biocides from the membrane, lowe

32 ition of general strategies to develop smart antibacterial drugs and devices based on nanosilver.

33 include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unm

34 ens is a valid target for the development of antibacterial drugs, and that the existing clinical agen

35 ty reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostri

36 is a potential target for new antifungal and antibacterial drugs as the shikimate pathway is absent f

37 unexploited antibiotics as a source of novel antibacterial drug candidates.

38 ognized as a promising target to develop new antibacterial drugs, catalyzes two key reactions: acetyl

39 t requires that patients take large doses of antibacterial drug combinations for at least 6 months af

40 rial cells makes it an attractive target for antibacterial drug design.

41 ibitors and is therefore a viable target for antibacterial drug design.

42 lian cells makes it an attractive target for antibacterial drug design.

43 and validates PDF as an excellent target for antibacterial drug design.

44 in the donor site, provides a direction for antibacterial drugs design.

45 Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity

46 formation Initiative (CTTI) seeks to advance antibacterial drug development (ABDD) by streamlining cl

47 asked with exploring economic incentives for antibacterial drug development and providing recommendat

48 formation Initiative (CTTI) seeks to advance antibacterial drug development by streamlining HABP/VABP

49 Antibacterial drug development suffers from a paucity of

50 biochemical tool for identifying targets for antibacterial drug development.

51 lycan, rendering it an attractive target for antibacterial drug development.

52 s, and ensure patient safety while advancing antibacterial drug development.

53 identification of novel systems suitable for antibacterial drug development.

54 sadvantages of different pull incentives for antibacterial drug development.

55 evaluation as potential starting points for antibacterial drug development.

56 nts a new, and as yet, untested paradigm for antibacterial drug development.

57 bacteria represents a promising strategy for antibacterial drug development.

58 rial species and are established targets for antibacterial drug development.

59 eas of consensus for economic incentives for antibacterial drug development.

60 This problem is significant for antibacterial drugs, difficult for antivirals, and utter

61 es, and opportunities in the natural product antibacterial drug discovery arena, and to emerging appl

62 The demise of antibacterial drug discovery brings the spectre of untre

63 fatty acid synthesis (FASII) as a target for antibacterial drug discovery in Gram-positive organisms

64 application of modern chemical synthesis to antibacterial drug discovery must play a critical role i

65 Faced with a wealth of antibacterial drug discovery targets as a result of bact

66 nce (MDR), which makes these pumps important antibacterial drug discovery targets.

67 nes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multi

68 genomes, making it an attractive target for antibacterial drug discovery.

69 transduction as a multicomponent target for antibacterial drug discovery.

70 bacteria and suggests a molecular target for antibacterial drug discovery.

71 crobe behavior analysis with applications in antibacterial drug discovery.

72 ng replication and are validated targets for antibacterial drug discovery.

73 mportantly, clomiphene represents a lead for antibacterial drug discovery.

74 itch-region inhibitors, and implications for antibacterial drug discovery.

75 yme A (CoA) biosynthesis and is a target for antibacterial drug discovery.

76 structures are a valuable resource to guide antibacterial drug discovery.

77 cellular targets are needed to reinvigorate antibacterial drug discovery.

78 ctures are also a valuable resource to guide antibacterial drug discovery.

79 c pathway, they are an attractive target for antibacterial drug discovery.

80 esses many of the requisite properties of an antibacterial drug, displaying potent and selective bact

81 The evaluation of new antibacterial drugs for efficacy in this population is i

82 international expert panel selected systemic antibacterial drugs for their potential to treat infecti

83 roidal anti-inflammatory and fluoroquinolone antibacterial drugs for transport appears to be present

84 molecules, which include protein toxins and antibacterial drugs, from the cell.

85 The potential of these antibiotics as antibacterial drugs has been enhanced by the elimination

86 Since the 1990s, the number of new antibacterial drugs has plummeted and the number of anti

87 acy in this population is important, as many antibacterial drugs have demonstrated limitations when s

88 mation has opened up many new strategies for antibacterial drug hunting.

89 ddress the AMR threat include new methods of antibacterial drug identification and strategies that ne

90 The extensive and unregulated use of antibacterial drugs in animal farms in Lebanon can lead

91 ed by one of the most widely used classes of antibacterial drugs in human clinical use today, beta-la

92 Eleven antibacterial drugs in late stage clinical development a

93 confirmation of the mode of action of novel antibacterial drugs in S. pneumoniae.

94 Many antitumor and antibacterial drugs inhibit DNA topoisomerases by trappi

95 are literally 'against life'--are typically antibacterial drugs, interfering with some structure or

96 The continued development of new antibacterial drugs is critical to meet patient and publ

97 The paucity of new antibacterial drugs is evident, and the arsenal against

98 njunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certa

99 stewater resulting from the production of an antibacterial drug (nalidixic acid) was investigated emp

100 mrE was screened for resistance to two major antibacterial drugs--norfloxacin, a fluoroquinolone, and

101 predictions concerning the lack of effective antibacterial drugs occur with increasing frequency.

102 aim is the creation of a sustainable global antibacterial drug research and development enterprise w

103 ctive mechanisms represent novel targets for antibacterial drug research.

104 from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif).

105 Quinolone antibacterial drugs such as nalidixic acid target DNA gy

106 This enzyme, ThyX, is a potential antibacterial drug target, since humans and most eukaryo

107 biosynthesis pathway and is a potential new antibacterial drug target.

108 nt in ligase evolution and favors LigA as an antibacterial drug target.

109 Quinolone antibacterial drugs target both DNA gyrase (Gyr) and top

110 Bacterial topoisomerases are attractive antibacterial drug targets because of their importance i

111 was developed to identify and prioritize the antibacterial drug targets in Clostridium botulinum (Clb

112 M. tuberculosis viability and are validated antibacterial drug targets, but the requirements for ass

113 es a promising approach to validation of new antibacterial drug targets.

114 cterial SBPs are of considerable interest as antibacterial drug targets.

115 gulation, riboswitches have been proposed as antibacterial drug targets.

116 y for the discovery of novel, yet unexplored antibacterial drug targets.

117 tate of DNA during replication and validated antibacterial drug targets.

118 flavin synthesis are considered as potential antibacterial drug targets.

119 for cell growth, and therefore may represent antibacterial drug targets.

120 modulate the effectiveness of many antitumor/antibacterial drugs that act by stabilizing cleavage-com

121 Novel antibacterial drugs that are effective against infection

122 There is an urgent need for new antibacterial drugs that are effective against infection

123 nstrates some progress in development of new antibacterial drugs that target infections caused by res

124 Quinolones are potent broad spectrum antibacterial drugs that target the bacterial type II DN

125 esearch to facilitate the development of new antibacterial drug therapies for treatment of hospital-a

126 Addition of antibacterial drugs to interim antibacterial cement spac

127 Diverse molecules, from small antibacterial drugs to large protein toxins, are exporte

128 To bring new antibacterial drugs to the market is challenging because

129 encoded DHFRs that confer resistance to the antibacterial drug trimethoprim.

130 ently in response to the clinical use of the antibacterial drug trimethoprim.

131 chanism to the increased clinical use of the antibacterial drug trimethoprim.

132 zyme that confers clinical resistance to the antibacterial drug trimethoprim.

133 reductase (DHFR) provides resistance to the antibacterial drug trimethoprim.

134 be probed by an in vivo selection using the antibacterial drug, trimethoprim, where the water conten

135 enzyme in bacteria confers resistance to the antibacterial drug, trimethoprim.

136 ncoded enzyme that confers resistance to the antibacterial drug, trimethoprim.

137 One hundred forty-eight antibacterial drugs were on shortage over the 13-year st

138 Therefore, modification of trimethoprim, an antibacterial drug with no tumor growth inhibition, led